Stockreport

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients [Yahoo! Finance]

Cerus Corporation  (CERS) 
Last cerus corporation earnings: 2/20 04:01 pm Check Earnings Report
PDF CONCORD, Calif., March 19, 2024 BUSINESS WIRE )--Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial [Read more]